D. Scott Ernst

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

I. F. Tannock, David Osoba, Martin R. Stockler et al. · Journal of Clinical Oncology · 1996 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +17

Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Daniel Y.C. Heng, J. Connor Wells, Brian I. Rini et al. · European Urology · 2014 · 474 citations · Full text

Medicine, Oncology, Surgery +15

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

Jenny J. Ko, Wanling Xie, Nils Kroeger et al. · The Lancet Oncology · 2015 · 375 citations · Full text

Medicine, Nephrology, Oncology +14

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

Malcolm J. Moore, Ian F. Tannock, D. Scott Ernst et al. · Journal of Clinical Oncology · 1997 · 274 citations

Medicine, Oncology, Pharmacotherapy +12

Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain

D. Scott Ernst, I. F. Tannock, Eric Winquist et al. · Journal of Clinical Oncology · 2003 · 248 citations

Pharmacy, Oncology, Pharmacotherapy +16